|
1
|
Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou
YM, Li CY and Yang Q: A novel crosstalk between BRCA1 and poly
(ADP-ribose) polymerase 1 in breast cancer. Cell Cycle.
13:3442–3449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saini KS, Loi S, de Azambuja E,
Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and
Piccart-Gebhart MJ: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK
pathways in the treatment of breast cancer. Cancer Treat Rev.
39:935–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weinstein-Oppenheimer CR, Burrows C,
Steelman LS and McCubrey JA: The effects of beta-estradiol on Raf
activity, cell cycle progression and growth factor synthesis in the
MCF-7 breast cancer cell line. Cancer Biol Ther. 1:256–262. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurvitz SA, Kalous O, Conklin D, Desai AJ,
Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R,
et al: In vitro activity of the mTOR inhibitor everolimus, in a
large panel of breast cancer cell lines and analysis for predictors
of response. Breast Cancer Res Treat. 149:669–680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu H, Hu C, Wu X and Li Z: Equol elicits
estrogenic activities via PI3K/akt pathway in the estrogen
receptor-positive MCF-7 cells. Mol Cell Toxicol. 10:285–291. 2014.
View Article : Google Scholar
|
|
6
|
Paplomata E and O'Regan R: The
PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and
biomarkers. Ther Adv Med Oncol. 6:154–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bjornsti MA and Houghton PJ: The TOR
pathway: A target for cancer therapy. Nat Rev Cancer. 4:335–348.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Newton J, Lima S, Maceyka M and Spiegel S:
Revisiting the sphingolipid rheostat: Evolving concepts in cancer
therapy. Exp Cell Res. 333:195–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ogretmen B: Sphingolipid metabolism in
cancer signalling and therapy. Nat Rev Cancer. 18:33–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Park WJ and Park JW: The effect of altered
sphingolipid acyl chain length on various disease models. Biol
Chem. 396:693–705. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park JW, Park WJ and Futerman AH: Ceramide
synthases as potential targets for therapeutic intervention in
human diseases. Biochim Biophys Acta. 1841:671–681. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karahatay S, Thomas K, Koybasi S, Senkal
CE, Elojeimy S, Liu X, Bielawski J, Day TA, Gillespie MB, Sinha D,
et al: Clinical relevance of ceramide metabolism in the
pathogenesis of human head and neck squamous cell carcinoma
(HNSCC): Attenuation of C18-ceramide in HNSCC tumors
correlates with lymphovascular invasion and nodal metastasis.
Cancer Lett. 256:101–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mesicek J, Lee H, Feldman T, Jiang X,
Skobeleva A, Berdyshev EV, Haimovitz-Friedman A, Fuks Z and
Kolesnick R: Ceramide synthases 2, 5, and 6 confer distinct roles
in radiation-induced apoptosis in HeLa cells. Cell Signal.
22:1300–1307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hartmann D, Lucks J, Fuchs S, Schiffmann
S, Schreiber Y, Ferreirós N, Merkens J, Marschalek R, Geisslinger G
and Grösch S: Long chain ceramides and very long chain ceramides
have opposite effects on human breast and colon cancer cell growth.
Int J Biochem Cell Biol. 44:620–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zigdon H, Kogot-Levin A, Park JW,
Goldschmidt R, Kelly S, Merrill AH Jr, Scherz A, Pewzner-Jung Y,
Saada A and Futerman AH: Ablation of ceramide synthase 2 causes
chronic oxidative stress due to disruption of the mitochondrial
respiratory chain. J Biol Chem. 288:4947–4956. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raichur S, Wang ST, Chan PW, Li Y, Ching
J, Chaurasia B, Dogra S, Öhman MK, Takeda K, Sugii S, et al: CerS2
haploinsufficiency inhibits β-oxidation and confers susceptibility
to diet-induced steatohepatitis and insulin resistance. Cell Metab.
20:9192014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park WJ, Park JW, Merrill AH, Storch J,
Pewzner-Jung Y and Futerman AH: Hepatic fatty acid uptake is
regulated by the sphingolipid acyl chain length. Biochim Biophys
Acta. 1841:1754–1766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maceyka M, Harikumar KB, Milstien S and
Spiegel S: Sphingosine-1-phosphate signaling and its role in
disease. Trends Cell Biol. 22:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strub GM, Maceyka M, Hait NC, Milstien S
and Spiegel S: Extracellular and intracellular actions of
sphingosine-1-phosphate. Adv Exp Med Biol. 688:141–155. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagahashi M, Tsuchida J, Moro K, Hasegawa
M, Tatsuda K, Woelfel IA, Takabe K and Wakai T: High levels of
sphingolipids in human breast cancer. J Surg Res. 204:435–444.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Erez-Roman R, Pienik R and Futerman AH:
Increased ceramide synthase 2 and 6 mRNA levels in breast cancer
tissues and correlation with sphingosine kinase expression. Biochem
Biophys Res Commun. 391:219–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan S, Niu Y, Tan N, Wu Z, Wang Y, You H,
Ke R, Song J, Shen Q, Wang W, et al: LASS2 enhances
chemosensitivity of breast cancer by counteracting acidic tumor
microenvironment through inhibiting activity of V-ATPase proton
pump. Oncogene. 32:1682–1690. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan SH, Wang YY, Lu J, Zheng YL, Wu DM,
Zhang ZF, Shan Q, Hu B, Li MQ and Cheng W: CERS2 suppresses tumor
cell invasion and is associated with decreased V-ATPase and
MMP-2/MMP-9 activities in breast cancer. J Cell Biochem.
116:502–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fekry B, Esmaeilniakooshkghazi A, Krupenko
SA and Krupenko NI: Ceramide synthase 6 is a novel target of
methotrexate mediating its antiproliferative effect in a
p53-dependent manner. PLoS One. 11:e01466182016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maeng HJ, Song JH, Kim GT, Song YJ, Lee K,
Kim JY and Park TS: Celecoxib-mediated activation of endoplasmic
reticulum stress induces de novo ceramide biosynthesis and
apoptosis in hepatoma HepG2 cells mobilization. BMB Rep.
50:144–149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Denard B, Lee C and Ye J: Doxorubicin
blocks proliferation of cancer cells through proteolytic activation
of CREB3L1. Elife. 1:e000902012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Merrill AH, van Echten G, Wang E and
Sandhoff K: Fumonisin B1 inhibits sphingosine (sphinganine)
N-acyltransferase and de novo sphingolipid biosynthesis in cultured
neurons in situ. J Biol Chem. 268:27299–27306. 1993.PubMed/NCBI
|
|
30
|
Cancer Genome Atlas Network, . Koboldt DC,
Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF,
Fulton LL, Dooling DJ, Ding L, Mardis ER, et al: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Woodcock J: Sphingosine and ceramide
signalling in apoptosis. IUBMB Life. 58:462–466. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shayman JA: Sphingolipids. Kidney Int.
58:11–26. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toss A and Cristofanilli M: Molecular
characterization and targeted therapeutic approaches in breast
cancer. Breast Cancer Res. 17:602015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Serra V, Scaltriti M, Prudkin L, Eichhorn
PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M,
Rodriguez S, et al: PI3K inhibition results in enhanced HER
signaling and acquired ERK dependency in HER2-overexpressing breast
cancer. Oncogene. 30:2547–2557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baselga J, Campone M, Piccart M, Burris HA
III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun
F, et al: Everolimus in postmenopausal hormone-receptor-positive
advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Piccart M, Hortobagyi GN, Campone M,
Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu
I, et al: Everolimus plus exemestane for hormone-receptor-positive,
human epidermal growth factor receptor-2-negative advanced breast
cancer: Overall survival results from BOLERO-2†. Ann Oncol.
25:2357–2362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Min J, Mesika A, Sivaguru M, Van Veldhoven
PP, Alexander H, Futerman AH and Alexander S: (Dihydro)ceramide
synthase 1 regulated sensitivity to cisplatin is associated with
the activation of p38 mitogen-activated protein kinase and is
abrogated by sphingosine kinase 1. Mol Cancer Res. 5:801–812. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blaho VA and Hla T: An update on the
biology of sphingosine 1-phosphate receptors. J Lipid Res.
55:1596–1608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schiffmann S, Sandner J, Birod K, Wobst I,
Angioni C, Ruckhäberle E, Kaufmann M, Ackermann H, Lötsch J,
Schmidt H, et al: Ceramide synthases and ceramide levels are
increased in breast cancer tissue. Carcinogenesis. 30:745–752.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gupta V, Bhinge KN, Hosain SB, Xiong K, Gu
X, Shi R, Ho MY, Khoo KH, Li SC, Li YT, et al: Ceramide
glycosylation by glucosylceramide synthase selectively maintains
the properties of breast cancer stem cells. J Biol Chem.
287:37195–37205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Novgorodov SA, Chudakova DA, Wheeler BW,
Bielawski J, Kindy MS, Obeid LM and Gudz TI: Developmentally
regulated ceramide synthase 6 increases mitochondrial
Ca2+ loading capacity and promotes apoptosis. J Biol
Chem. 286:4644–4658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu J, Novgorodov SA, Chudakova D, Zhu H,
Bielawska A, Bielawski J, Obeid LM, Kindy MS and Gudz TI: JNK3
signaling pathway activates ceramide synthase leading to
mitochondrial dysfunction. J Biol Chem. 282:25940–25949. 2007.
View Article : Google Scholar : PubMed/NCBI
|
